COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03672318
Recruitment Status : Recruiting
First Posted : September 14, 2018
Last Update Posted : May 26, 2020
Information provided by (Responsible Party):
UNC Lineberger Comprehensive Cancer Center

Brief Summary:

The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body from disease caused by bacteria or toxic substances. Antibodies work by binding those bacteria or substances, which stops them from growing and causing bad effects. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected. Both antibodies and T cells have been used to treat patients with cancers. They both have shown promise, but neither alone has been sufficient to cure most patients. This study is designed to combine both T cells and antibodies to create a more effective treatment. The treatment that is being researched is called autologous T lymphocyte chimeric antigen receptor cells targeted against the CD138 antigen (CAR138 T cells).

In previous studies, it has been shown that a new gene can be put into T cells that will increase their ability to recognize and kill cancer cells. A gene is a unit of DNA. Genes make up the chemical structure carrying the patient's genetic information that may determine human characteristics (i.e., eye color, height and sex). The new gene that is put in the T cells in this study makes a piece of an antibody called anti-CD138. This antibody floats around in the blood and can detect and stick to cancer cells called multiple myeloma cells because they have a substance on the outside of the cells called CD138. Anti-CD138 antibodies have been used to treat people with multiple myeloma, but have not been strong enough to cure most patients. For this study, the anti-CD138 antibody has been changed so that instead of floating free in the blood part of it is now joined to the T cells. Only the part of the antibody that sticks to the multiple myeloma cells is attached to the T cells instead of the entire antibody. When an antibody is joined to a T cell in this way it is called a chimeric receptor. These CD138 chimeric (combination) receptor-activated T cells seem to kill some of the tumor, but they do not last very long in the body and so their chances of fighting the cancer are unknown.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Immune System Diseases Drug: CAR138 T Cells Phase 1

Detailed Description:

Cell Procurement Up to 300 mL total of peripheral blood (up to 3 collections) will be obtained from patients for cell procurement. In patients with a low CD3 count in the peripheral blood (less than 200/μl by flow cytometry), a leukopheresis may be performed to isolate sufficient T-cells. The parameters for pheresis will be 2 blood volumes.

CAR138 T-cell Administration Autologous CAR138 T-cells will be administered 2-14 days following lymphodepletion. The lymphodepletion regimen will consist of Cyclophosphamide 300 mg/m^2 and Fludarabine 30 mg/m^2 IV each given daily over 3 consecutive days.

Duration of Therapy Autologous CAR138 T-cells will be administered 2-14 days following lymphodepletion with cyclophosphamide and fludarabine by a licensed provider (oncology registered nurse or physician) via intravenous injection over 5-10 minutes through either a peripheral or central line. The expected volume is 1-50cc.

Treatment with one infusion will be administered unless:

  • The patient decides to withdraw from the study, OR
  • General or specific changes in the patient's condition render the patient unacceptable for further treatment in the judgment of the investigator.

Duration of Follow-up Patients will be followed for up to 15 years for replication-competent retrovirus evaluation or until death, whichever occurs first. Patients removed from study for unacceptable adverse events will continue follow up for evaluation of progression free survival, overall survival and replication-competent retrovirus monitoring.

Patients who experience disease progression after receiving a cell infusion will still be required to complete abbreviated follow up procedures.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 33 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of Autologous CAR T-Cells Targeting the CD138 Antigen for Relapsed or Refractory Multiple Myeloma
Actual Study Start Date : January 14, 2019
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : October 2032

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: CAR138 T cells
The first 3 patients enrolled in the study will receive 5x10^6 CAR138 T-cells/m^2 via infusion. The number of cells for the infusion will be increased to 1x10^7 CAR138 T-cells/m^2 and then, 2.5x10^7 CAR138 T-cells/m^2, 5x10^7 CAR138 T-cells/m^2, 1x10^8 CAR138 T-cells/m^2 and 2x10^8 CAR138 T-cells/m^2 in subsequent cohorts of 3 patients provided no dose limiting toxicities (DLTs) are observed within 4 weeks of the cell infusion. Cohort enrollment will be staggered, requiring each patient to complete at least 2 weeks of safety monitoring following CAR138 T-cell infusion at the designated dose level for the cohort before another patient is allowed to enroll in the cohort.
Drug: CAR138 T Cells

The MTD is defined as the dose at which approximately 0.20 of patients experience DLT dose escalation guided by the continual reassessment method (CRM).

Six dose levels will be evaluated:

Dose level 1: 5X10^6 cells/m^2 Dose level 2: 1X10^7 cells/m^2 Dose level 3: 2.5X10^7 cells/m^2 Dose level 4: 5X10^7 cells/m^2 Dose level 5: 1x10^8 cells/m^2 Dose level 6: 2x10^8 cells/m^2

Six patients will be enrolled at the MTD to better characterize safety at that dose level.

Cell Administration: CAR138 T cells will be given by intravenous injection over through either a peripheral or a central line.

The lymphodepletion regimen will consist of intravenous cyclophosphamide 300 mg/m^2 and fludarabine 30 mg/m^2 given once daily for three days.

Other Names:
  • ATLCAR.CD138
  • CAR.CD138 T cells

Primary Outcome Measures :
  1. Proportion of participants with dose limiting toxicities as a measure of maximum tolerated dose of CAR138 T cells [ Time Frame: 4 weeks from infusion of the CAR138 T cells ]
    The maximum tolerated dose will be determined through assessment of dose limiting toxicity (DLT) experienced during the safety evaluation period. Severity and categorization of adverse events will be determined in accordance with the National Cancer Institute's Common Terminology for Adverse Events (CTCAE, version 5.0). A DLT is defined as any of the following that may, after consultation with the FDA, be considered possibly, probably, or definitely related to the study cellular products: Grade 3 and 4 cytokine release syndrome (CRS) that persists beyond 72 hours, or any Grade 5 CRS event; Grade 4 neutropenia or thrombocytopenia lasting more than 28 days from the time of CAR138 T-cell infusion. Any other ≥ Grade 3 non- hematologic toxicity (exceptions include: alopecia; grade 3 electrolyte abnormalities, hyperglycemia, diarrhea, or nausea and vomiting that can be managed with supportive care and do not persist as Grade 3 toxicities for > 72 hours)).

Secondary Outcome Measures :
  1. Survival of CAR138 T cells in vivo as assessed by PCR and flow cytometry [ Time Frame: 15 years ]
    Persistence of CAR138 T-cells in vivo determined by quantitative polymerase chain reaction (PCR) and flow cytometry in samples of peripheral blood.

  2. Overall survival after infusion of CAR138 T cells [ Time Frame: 15 years ]
    To determine the overall survival (OS) after infusion of CAR138 T cells in patients with relapsed or refractory multiple myeloma. OS will be measured from the date of administration of CAR138 T-cells to the date of death

  3. Progression free survival after infusion of CAR138 T cells [ Time Frame: 15 years ]
    Progression Free Survival (PFS) is the time from infusion of CAR138 T cells to progression or death from any cause. Patients not known to have progressed or died at last follow-up are censored on the date of last contact. Revised Uniform Response Criteria by the International Myeloma Working Group defines progression as: Increase of 25% from lowest response value in: Serum M component with absolute increase (AI) ≥0.5 g/dL; serum M component increase ≥1 g/dL if starting M component is ≥5 g/dL and/or; Urine M component (AI ≥200 mg/24 h) and/or; in patients without measureable serum & urine M-protein levels: difference between involved & uninvolved FLC levels (AI > 10 mg/dL); in patients without measurable serum & urine M-protein levels, without measurable disease by FLC level, bone marrow; Development of new or definite increase in size of existing bone lesions or soft tissue plasmacytoma; Development of hypercalcemia that can be attributed solely to plasma cell proliferative disorder.

  4. Overall response rate (ORR) as defined as the percentage of patients achieving a confirmed partial response or better based on the International Myeloma Working Group (IMWG) response criteria. [ Time Frame: 15 years ]
    ORR, percentage of patients achieving a partial response or better: Complete response (CR) is Negative immunofixation of serum and urine, disappearance of soft tissue plasmacytomas, and <5% plasma cells in bone marrow (BM); stringent complete response (sCR) CR plus normal FLC ratio and absence of clonal plasma cells; Immunophenotypic CR- sCR plus absence of phenotypically aberrant plasma cells in BM with minimum of 1 million total BM cells; Molecular CR -CR plus negative allele-specific oligonucleotide polymerase chain reaction. Very good partial response -Serum and urine M component detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M component plus urine M component <100/24h; Partial response ≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein by ≥90% or to <200 mg per 24 hr; no known evidence of progressive or new bone lesions if radiographic studies were performed.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Eligibility Criteria:

  • Written informed consent and HIPAA authorization for release of personal health information. Patients must sign a consent to undergo cell procurement. Written informed consent to enroll in the CAR T-cell therapy trial must be obtained prior to lymphodepletion.
  • Age ≥ 18 years at the time of consent.
  • Karnofsky score of ≥ 60%.
  • Diagnosis of relapsed or refractory multiple myeloma (as defined by the Revised Uniform Response Criteria outlined by the IMWG
  • Measurable disease as defined by one or more of the following: 1) serum M-protein ≥1.0 g/dL (≥0.5 g/dL for immunoglobulin A myeloma); 2) urine M-protein ≥200 mg/24 hours; 3) involved serum free light chain level ≥10 mg/dL AND an abnormal serum free light chain ratio. Patients with non-secretory disease and a baseline marrow burden of myeloma of at least 30% will also be eligible to participate.

    • Two lines of therapy will be allowed if the patient has disease that is refractory to both an immunomodulatory agent (lenalidomide or pomalidomide) and a proteasome inhibitor.
  • Received high dose melphalan followed by autologous stem-cell transplant or is not eligible for or has declined the procedure.
  • Allogeneic stem cell transplantation is allowed provided the patient is ≥ 1 year from transplant, not on immunosuppressive therapy to treat/prevent graft-versus-host disease, has no evidence of active graft-versus-host disease, and has no evidence of active graft-versus-host disease or infection.
  • Demonstrate adequate organ function prior to cell procurement as defined below:

    • Creatinine Clearance using the Cockcroft-Gault formula: ≥ 50 mL/min
    • Bilirubin: ≤ 1.5 × upper limit of normal (ULN)
    • Aspartate aminotransferase (AST): ≤ 2.5 × ULN
    • Alanine aminotransferase (ALT): ≤ 2.5 × ULN
    • Oxygen saturation: ≥ 92% on room air
    • Forced expiratory volume at 1 second (FEV1), forced vital capacity (FVC), total lung capacity (TLC), diffusion capacity of lung for carbon monoxide (DLCO): ≥ 50% of predicted values
    • Ejection fraction: ≥ 50%
    • Hemoglobin: ≥ 8.0 g/dL; transfusion of red blood cells within 1 weeks will be permitted
    • Platelets: ≥ 50,000 /mm^3; Patients should not have received platelet transfusions within 1 week of screening
    • ANC: ≥ 1000 /mm^3; Patients should not have received Granulocyte-colony stimulating factor (G-CSF) or Granulocyte macrophage colony-stimulating factor (GM-CSF) within 1 week or pegylated G-CSF (Neulasta) within 2 weeks of screening
  • Negative serum pregnancy test within 72 hours prior to procurement and again 72 hours prior to lymphodepleting therapy for female participants of child bearing potential. NOTE: Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months.
  • Women of childbearing potential (WOCBP) should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study, and for 6 months after the study is concluded. WOCBP are those who have not been surgically sterilized or have not been free from menses for > 1 year. The two birth control methods can be composed of: two barrier methods or a barrier method plus a hormonal method to prevent pregnancy. The male partner of WOCBP patients enrolled into the trial should use a condom and female participants must take the responsibility to inform their partners of the need to use a condom. As determined by the enrolling physician or protocol designee, ability of the patient to understand and comply with study procedures for the entire length of the study.
  • Male patients with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) prior to lymphodepletion through 3 months after the last dose of study therapy.
  • No active infection (fungal, bacterial or viral) including Human Immunodeficiency Virus (HIV), Human T-lymhotropic virus (HTLV), Hepatits B virus (HBV), Hepatitis C virus (HCV) (tests can be pending at the time of cell procurement; only those samples confirming lack of active infection will be used to generate transduced cells). Note: To meet eligibility, patients are required to be negative for HIV antibody or HIV viral load, negative for HTLV1 and 2 antibody or PCR negative for HTLV1 and 2, negative for Hepatitis B surface antigen, and negative for HCV antibody or HCV viral load.
  • Not pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
  • No tumor in a location where enlargement could cause airway obstruction.
  • No history of hypersensitivity reactions to murine protein-containing products.
  • No known sensitivity to mouse monoclonal antibodies.
  • Has not received treatment with any investigational drug within 21 days or any tumor vaccines within the previous six weeks prior to lymphodepletion.
  • No major surgery within 28 days prior to lymphodepletion.
  • No diagnosis of any of the following conditions: amyloidosis, POEMS syndrome or multiple myeloma with central nervous system involvement.

    • Patients with plasma cell leukemia are allowed to participate.
  • No active inflammatory or infectious gastrointestinal disorder (e.g. infectious colitis, diverticulitis or inflammatory bowel disease).
  • No psychiatric illness which would prevent the patient from giving informed consent.
  • No medical condition which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient.
  • No other prior or concomitant malignancies with the exception of:

    • Non-melanoma skin cancer
    • In-situ malignancy
    • Low-risk prostate cancer after curative therapy
    • Other cancer for which the patient has been disease free for ≥ 3 years.
  • Adequate cardiac function, defined as:

    • No EKG evidence of acute ischemia
    • No EKG evidence of active, clinically significant conduction system abnormalities
    • Prior to study entry, any EKG abnormality at screening not felt to put the patient at risk has to be documented by the investigator as not medically significant
    • No uncontrolled angina or severe ventricular arrhythmias
    • No clinically significant pericardial disease
    • No history of myocardial infarction within the last 6 months prior to registration
    • No Class 3 or higher New York Heart Association Congestive Heart Failure
  • To qualify for lymphodepletion and CAR138 T-cell infusion, patients must meet all of the above eligibility criteria. A repeat EKG, echocardiogram or multigated acquisition scan, pulmonary function tests and viral serologies do not need to be repeated unless clinically indicated. In addition:

    • Patients must have autologous transduced activated CAR 138 T-cells with appropriate transduction efficiency (as discussed with FDA)
    • Patients must have autologous transduced activated CAR138 T-cells with ≥15% expression of CAR138
  • Patients must have stopped taking corticosteroids for at least 48 hours prior to lymphodepleting chemotherapy; (those receiving <10mg/day prednisone equivalent may be enrolled at discretion of investigator)
  • Patients must have stopped systemic chemotherapy for at least 14 days prior to lymphodepletion
  • Patients must have stopped radiation therapy for at least 7 days prior to lymphodepletion
  • Patients should have repeat multiple myeloma serologies performed within 7 days of lymphodepletion. If markers of measurable disease no longer fall within the guidelines outlined above (eligibility criterion #5), the Principal Investigator should be contacted. In such an event, the patient may be allowed to receive lymphodepletion and CAR138 T-cell infusion if it is felt to be in the patient's best interests. The patient would not be evaluable for response (disease not measurable) but would be evaluable for all other safety and efficacy measures.
  • Patients must demonstrate adequate organ function prior to lymphodepletion as defined in the table below; all tests must be obtained within 48 hours prior to lymphodepletion.

    • Hemoglobin: ≥ 8 g/dL
    • Absolute Neutrophil Count (ANC): ≥ 1000 cells/mm^3; patients should not have received G-CSF or GM-CSF within 1 week or pegylated G-CSF (Neulasta) within 2 weeks of screening for lymphodepletion
    • Platelets: ≥ 50,000 cells/mm^3; patients should not have received platelet transfusion within 1 week of screening for lymphodepletion
    • Calculated creatinine clearance: ≥ 50 mL/min using the Cockcroft-Gault formula
    • Bilirubin: ≤ 1.5 × upper limit of normal (ULN)
    • Aspartate aminotransferase (AST): ≤ AST ≤ 2.5 × ULN
    • Alanine aminotransferase (ALT): ≤ AST ≤ 2.5 × ULN
    • Pulse oximetry: ≥92% on room air

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03672318

Layout table for location contacts
Contact: Catherine Cheng 919-445-4208
Contact: Spencer Laing 919-962-8618

Layout table for location information
United States, North Carolina
Lineberger Comprehensive Cancer Center at University of North Carolina Recruiting
Chapel Hill, North Carolina, United States, 27599
Contact: Catherine Cheng    919-445-4208   
Contact: Spencer Laing    919-962-8618   
Principal Investigator: Sascha Tuchman, MD, MPS         
Sponsors and Collaborators
UNC Lineberger Comprehensive Cancer Center
Layout table for investigator information
Principal Investigator: Sascha Tuchman, MD, MHS Assoc. Professor, Dir. of the UNC MM and Amyloidosis Program, UNC LCCC
Additional Information:
Layout table for additonal information
Responsible Party: UNC Lineberger Comprehensive Cancer Center Identifier: NCT03672318    
Other Study ID Numbers: LCCC 1603-ATL
First Posted: September 14, 2018    Key Record Dates
Last Update Posted: May 26, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by UNC Lineberger Comprehensive Cancer Center:
CAR T cells
Multiple Myeloma
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Immune System Diseases
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders